Avacta secures second Optim sale in US
2 June 2011
Avacta Group plc has announced that its newly appointed sales
and marketing partner for Optim in North America, Pall Corporation, has
secured its first Optim sale, to one of the ten largest pharmaceutical
companies in the US.
Optim reduces the time and cost of drug development through the
early analysis of compounds to identify those candidates most
suitable for development and to define the optimal processing
conditions. In the critical stages of pre-formulation, stability
testing and formulation of biopharmaceutical drugs, Optim delivers
vital information tens of times faster than other approaches using
sample sizes less than a hundredth needed by existing techniques.
Alastair Smith, Chief Executive of Avacta Group commented, “The
US is the major market for Optim and I am delighted with the
energetic and proactive start that Pall has made as our commercial
partner in North America. ... Today’s order means we have already
met the target of twelve Optim sales in the current year. I look
forward to reporting on further sales in due course and on the wider
development of the commercial relationship with Pall.”
Source: Avacta